Lung
LF/TERT309
Evercyte ́s human lung fibroblast cell line LF/TERT309 can be grown without limitations while maintaining expression of cell type specific markers and functions. Therefore, these cells are valuable as standardized in vitro model to study pulmonary function and pathophysiology such as airway inflammation and remodeling or production of extracellular matrix compounds.
General information
Cat#: CHT-067-0309
Morphology and marker expression
LF/TERT309 cells are characterized by the typical, spindle shaped morphology of fibroblastoid cells and homogenously express the fibroblast marker Vimentin. Cell nuclei are counterstained with DAPI.
Growth characteristics
LF/TERT309 cells can be grown for a minimum of 60 population doublings with a stable growth rate and without showing signs of growth retardation.
Myofibroblast differentiation / induction alpha SMA expression
Treatment of telomerized human lung fibroblasts LF/TERT309 with transforming growth factor beta (TGF-ß) induces expression of alpha smooth muscle actin (𝛂-SMA), indicating myofibroblast differentiation.
Treatment of telomerized human lung fibroblasts LF/TERT309 with transforming growth factor beta (TGF-ß) together with PP2, an inhibitor of Src familiy of tyrosine kinases, attenuates the response of the cells to TGF-ß.
In vitro propagation
DMEM/Ham´s F12 with FBS and G418
DMEM/Ham´s F12 (1:1) (PAN Biotech, Cat# P04-41150)
10 % FBS (PAN Biotech, Cat# P30-3031)
Additional material & reagents
0,05 % Trypsin-EDTA (Gibco, Cat#25300-054)
Passaging of cells
For detachment of the cells remove and discard the culture medium and wash the cells once with PBS (about 160 µl/cm²). Remove PBS completely.
Cryopreservation
Freezing medium
DMEM/Ham´s F12 (1:1) (PAN Biotech, Cat# P04-41150)
10 % FBS (PAN Biotech, Cat# P30-3031)
10 % DMSO (Sigma Aldrich, Cat# D2650)
Additional material & reagents
Phosphate buffered saline (PBS) (Sigma, Cat# D8537)
0,05 % Trypsin-EDTA (Gibco, Cat#25300-054)
Freezing of cells
Detach the cells from the culture vessel by using Trypsin-EDTA solution (Protocol passaging of LF/TERT309)
Thawing of cells
Original Evercyte cells are to be thawed in a T25 roux flask.
Licence Conditions
The business concept of Evercyte is to out-license telomerized cells to our customers. The license conditions depend on whether the contract partner is a for profit or a nonprofit organization and the intended use of the cells.
Nonprofit organizations
On time payment for unlimited use: EUR 1600
Profit organizations
Pharmaceutical – chemical – cosmetic industries
Contract research organizations (CRO)
Initial license fee for 3 months: EUR 2500Annual license fee R&D: royalty based
Customer Reviews
“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”
Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.
“Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform. We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed.”
Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.
New document on
Good Cell Culture Practice 2.0
ALTEX 39(1), 030-070
Customer Reviews
“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”
Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.
“Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform. We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed.”
Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.